Chronic Pain Clinical Trial
Official title:
Effect of Pain Catastrophizing on Prescription Opioid Craving
Adherence to prescription opioid and opioid tapering as indicated are critical for safe chronic opioid therapy for chronic pain, but this can be difficult for patients experiencing prescription opioid craving. Because pain catastrophizing is proposed as a possible treatment target by our and others' preliminary results, the proposed study aims to determine whether pain catastrophizing is a treatment target to reduce prescription opioid craving and to investigate whether negative affect and stress hormones are potential mediators. The findings from the current study will inform whether a psychology intervention to lower pain catastrophizing will reduce opioid craving, and whether psychological and physical distress as well as cognitive function will be potential mediators of the treatment effect.
Status | Recruiting |
Enrollment | 156 |
Est. completion date | June 30, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - At least 18 years - Chronic pain ( > 3months) - Prescription opioid use (>3 months) Exclusion Criteria: - Current diagnosis of cancer - Concurrent psychological therapy - Other severe psychiatric conditions (schizophrenia, delusional disorder, psychotic disorder, dissociative disorder, and active suicidality) - Any skin conditions on the hand (pain testing site) - Non-English speaker - No access to email or smart phone |
Country | Name | City | State |
---|---|---|---|
United States | SNAPL | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | craving | Visual analogue scale 0-100 will be used to measure daily craving | At day 7 (after intervention) | |
Primary | craving | Visual analogue scale 0-100 will be used to measure daily craving | At day 14 (7 days after intervention) | |
Secondary | Cortisol | Salivary cortisol will be collected at wake up, 30-min after waking up, and 9pm | At day 7 (after intervention) | |
Secondary | Cortisol | Salivary cortisol will be collected at wake up, 30-min after waking up, and 9pm | At day 14 (7 days after intervention) | |
Secondary | Anxiety symptoms | Patient-Reported Outcomes Measurement Information System-Anxiety item bank will be administered | At day 7 (after intervention) | |
Secondary | Anxiety symptoms | Patient-Reported Outcomes Measurement Information System-Anxiety item bank will be administered | At day 14 (7 days after intervention) | |
Secondary | Depression symptoms | Patient-Reported Outcomes Measurement Information System-Depression item bank will be administered | At day 7 (after intervention) | |
Secondary | Depression symptoms | Patient-Reported Outcomes Measurement Information System-Depression item bank will be administered | At day 14 (7 days after intervention) | |
Secondary | Prescription opioid misuse | Current Opioid Misuse Measure will be administered | At day 14 (7 days after intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|